Clinical trial
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual…
NCT00425256 · Palatin Technologies, Inc, Industry · Completed
Key facts
| NCT number | NCT00425256 |
|---|---|
| Title | Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) |
| Lead sponsor | Palatin Technologies, Inc, Industry |
| Collaborators | King Pharmaceuticals is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sexual Arousal Disorder |
| Intervention type | Drug |
| Interventions | Bremelanotide |
| Start date | Feb 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Jan 22, 2007 |
| Last update posted | Feb 23, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: